Physicians' Academy for Cardiovascular Education

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD
Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD
Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.

Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.

Icosapent ethyl reduces both first and total CV events in diabetes patients

News - June 16, 2020

ADA 2020 A prespecified analysis from REDUCE-IT demonstrated that first and total (first plus recurrent) CV events were reduced with icosapent ethyl compared to placebo in patients with diabetes.

ATP citrate lyase inhibitor lowers LDL-c across glycemic status subgroups

News - June 16, 2020

ADA 2020 The ATP citrate lyase inhibitor bempedoic acid lowered LDL-c compared to placebo in high-risk CV patients across all glycemic status subgroups, shown by a pooled analysis from four phase 3 trials.

SGLT2i reduces risk of new-onset T2DM

News - June 15, 2020

ADA 2020 The SGLT2 inhibitor dapagliflozin reduced risk of new-onset T2DM in HFrEF patients, demonstrated by a prespecified analysis of the DAPA-HF trial.

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD
The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.

Prevention and management of CVD in diabetes patients in the COVID-19 era

News - June 2, 2020

Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.

Icosapent ethyl reduces coronary revascularization

News - May 20, 2020
Administration of 4 g/day icosapent ethyl reduced first coronary revascularizations by 34% compared to placebo in patients with elevated triglyceride levels, who had CVD or diabetes with additional CV risk factors.

Administration of 4 g/day icosapent ethyl reduced first coronary revascularizations by 34% compared to placebo in patients with elevated triglyceride levels, who had CVD or diabetes with additional CV risk factors.

Practical recommendations for management of diabetes during COVID-19 pandemic

News - May 19, 2020

A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.

HF and CKD most frequent first CV- and renal disease manifestations in T2DM

Literature - May 18, 2020 - Birkeland KI et al., - Diabetes Obes Metab. 2020.

This study showed that the most frequent first manifestations of CV- and renal disease in T2DM patients were HF and CKD, which were both associated with increased all-cause and CVD mortality risk.

Primary endpoint of non-inferiority met for SGLT2i in CV outcomes trial

News - May 14, 2020

The phase 3 VERTIS CV outcomes trial with the SGLT2 inhibitor ertugliflozin has achieved its primary endpoint of non-inferiority for MACE in T2DM patients with established ASCVD.

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020
COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.

ACC 2020 COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.